HairDX said that it will soon begin recruiting post menopausal women as patients for the study. Women who qualify for the study will undergo genetic screening. If they exhibit a particular genetic variation in their androgen receptor gene, they will receive a drug that may potentially re-grow their hair. The trial is expected to start in the early fall.
Andy Goren, chairman and chief strategist of PharmaGenoma and HairDX, said: “Our goal is to revolutionize the field of dermatology by innovating genetically tailored treatments to common skin disorders.”
Antonella Tosti, professor of dermatology at the University of Bologna in Italy, said: “To date, no systemic drug treatment is available for female androgenetic alopecia. The HairDX drug trial may usher a new era in the treatment of female androgenetic alopecia.”